By a News Reporter-Staff News Editor at Gene Therapy Weekly -- A new study on Lipid Research is now available. According to news reporting originating in London, United Kingdom, by NewsRx journalists, research stated, "The role of lipid lowering in reducing the risk of mortality and morbidity from cardiovascular disease (CVD) is well established. Treatment particularly aimed at decreasing low-density lipoprotein cholesterol (LDL-C) is effective in reducing the risk of death from coronary heart disease and stroke."
The news reporters obtained a quote from the research from St. Thomas Hospital, "Statins form the cornerstone of treatment. However, in some individuals with a high risk of CVD who are unable to achieve their target LDL-C due to either intolerance or lack of efficacy, there is the need for alternative therapies. This review provides an overview of the different classes of currently available lipid-lowering medications including statins, fibrates, bile acid sequestrants (resins), and omega-3 fatty acids. Data are presented on their indications, pharmacology, and the relevant end point clinical trial data with these drugs. It also discusses the human trial data on some novel therapeutic agents that are being developed including those for homozygous familial hypercholesterolemiathe antisense oligonucleotide mipomersen and the microsomal transfer protein inhibitor lomitapide. Data are presented on phase II and III trials on agents with potentially wider applications, cholesterol ester transfer protein inhibitors and proprotein convertase subtilisin kexin 9 inhibitors."
According to the news reporters, the research concluded: "The data on a licensed gene therapy for lipoprotein lipase deficiency are also presented."
For more information on this research see: Lipid-Lowering Agents. Journal of Cardiovascular Pharmacology and Therapeutics, 2013;18(5):401-411. Journal of Cardiovascular Pharmacology and Therapeutics can be contacted at: Sage Publications Inc, 2455 Teller Rd, Thousand Oaks, CA 91320, USA. (Sage Publications - www.sagepub.com/; Journal of Cardiovascular Pharmacology and Therapeutics - cpt.sagepub.com)
Our news correspondents report that additional information may be obtained by contacting M. Ewang-Emukowhate, St. Thomas Hospital, Dept. of Chem Pathol, London SE1 9RT, United Kingdom (see also Lipid Research).
Keywords for this news article include: Antisense Technology, Biotechnology, London, Europe, Treatment, Gene Therapy, Therapeutics, United Kingdom, Bioengineering, Lipid Research, Clinical Trials and Studies
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC